Zobrazeno 1 - 9
of 9
pro vyhledávání: '"David Hersi Smith"'
Autor:
David Hersi Smith, Ib Jarle Christensen, Niels Frank Jensen, Bo Markussen, Maria Unni Rømer, Sune Boris Nygård, Sven Müller, Hans Jørgen Nielsen, Nils Brünner, Kirsten Vang Nielsen
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60613 (2013)
BackgroundTopoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism, frequency and
Externí odkaz:
https://doaj.org/article/322a7ecea97547bfa7fddff12c3549c1
Autor:
Nils Brünner, Ben Vainer, Ib Jarle Christensen, Maria Unni Rømer, Sven Müller, David Hersi Smith, Kirsten Vang Nielsen, Sune Boris Nygård, Hans Jørgen Nielsen, Signe Lykke Nielsen
Publikováno v:
Molecular Oncology. 7:101-111
Purpose A Topoisomerase 1 (Top1) poison is frequently included in the treatment regimens for metastatic colorectal cancer (mCRC). However, no predictive biomarkers for Top1 poisons are available. We here report a study on the TOP1 gene copy number in
Autor:
Sune Boris Nygård, Kirsten Vang Nielsen, Nils Brünner, Maria Unni Rømer, David Hersi Smith, Niels Frank Jensen
Publikováno v:
Scandinavian Journal of Gastroenterology. 47:340-355
The availability of systemic chemotherapy regimens for the treatment of patients with metastatic colorectal cancer (mCRC) is based on the results from large prospective, randomized studies. The main chemotherapeutic drugs used in treatment of mCRC ar
Autor:
Jan Stenvang, Hans Jørgen Nielsen, Nils Brünner, Sussie Steen Jensen, Tine Plato Hansen, Kirsten Vang Nielsen, Anne-Marie Kanstrup Fiehn, David Hersi Smith, Louise Fogh, Ib Jarle Christensen, Jane Preuss Hasselby
Publikováno v:
Scientific Reports
Smith, D H, Fiehn, A M K, Fogh, L, Christensen, I J, Hansen, T P, Stenvang, J, Nielsen, H J, Nielsen, K V, Hasselby, J P, Brunner, N & Jensen, S S 2014, ' Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody ', Scientific Reports, vol. 4, 4313 . https://doi.org/10.1038/srep04313
Smith, D H, Fiehn, A-M K, Fogh, L, Christensen, I J, Hansen, T P, Stenvang, J, Nielsen, H J, Nielsen, K V, Hasselby, J P, Brünner, N & Jensen, S S 2014, ' Measuring ERCC1 protein expression in cancer specimens : validation of a novel antibody ', Scientific Reports, vol. 4, 4313, pp. 1-8 . https://doi.org/10.1038/srep04313
Smith, D H, Fiehn, A M K, Fogh, L, Christensen, I J, Hansen, T P, Stenvang, J, Nielsen, H J, Nielsen, K V, Hasselby, J P, Brunner, N & Jensen, S S 2014, ' Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody ', Scientific Reports, vol. 4, 4313 . https://doi.org/10.1038/srep04313
Smith, D H, Fiehn, A-M K, Fogh, L, Christensen, I J, Hansen, T P, Stenvang, J, Nielsen, H J, Nielsen, K V, Hasselby, J P, Brünner, N & Jensen, S S 2014, ' Measuring ERCC1 protein expression in cancer specimens : validation of a novel antibody ', Scientific Reports, vol. 4, 4313, pp. 1-8 . https://doi.org/10.1038/srep04313
Platinum chemotherapy remains part of standard therapies in the management of a variety of cancers. Severe side effects and a high degree of resistance to platinum drugs have led numerous researchers to search for predictive biomarkers, which could a
Autor:
David Hersi Smith, Ib Jarle Christensen, Nils Brünner, Signe Lykke Nielsen, Hans Jørgen Nielsen, Sune Boris Nygård, Ben Vainer, Niels Frank Jensen
Publikováno v:
Scandinavian journal of gastroenterology. 48(12)
OBJECTIVE. We propose a repurposing strategy where anthracyclines are reintroduced to a subgroup of patients with metastatic colorectal cancer with the highest likelihood of response. In breast cancer, DNA topoisomerase II alpha gene (TOP2A) alterati
Autor:
Kirsten Vang Nielsen, Bo Markussen, Ib Jarle Christensen, Sven Müller, Hans Jørgen Nielsen, Maria Unni Rømer, David Hersi Smith, Niels Frank Jensen, Nils Brünner, Sune Boris Nygård
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60613 (2013)
Smith, D H, Christensen, I J, Jensen, N F, Markussen, B, Rømer, M U K, Nygård, S B, Müller, S, Nielsen, H J, Brünner, N & Nielsen, K V 2013, ' Mechanisms of topoisomerase I ( TOP1 ) gene copy number increase in a stage III colorectal cancer patient cohort ', P L o S One, vol. 8, no. 4, e60613 . https://doi.org/10.1371/journal.pone.0060613
PLoS ONE
Smith, D H, Christensen, I J, Jensen, N F, Markussen, B, Rømer, M U K, Nygård, S B, Müller, S, Nielsen, H J, Brünner, N & Nielsen, K V 2013, ' Mechanisms of topoisomerase I ( TOP1 ) gene copy number increase in a stage III colorectal cancer patient cohort ', P L o S One, vol. 8, no. 4, e60613 . https://doi.org/10.1371/journal.pone.0060613
PLoS ONE
BackgroundTopoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism, frequency and
Autor:
Niels Frank Jensen, Hans Jørgen Nielsen, Bo Markussen, Kirsten Vang Nielsen, Nils Brünner, David Hersi Smith, Sven Müller, Ib Jarle Christensen
Publikováno v:
BMC Cancer
Smith, D H, Christensen, I J, Jensen, N F, Markussen, B, Müller, S, Nielsen, H J, Brünner, N & Nielsen1,7, K V 2013, ' An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort ', BMC Cancer, vol. 13, 13:489 . https://doi.org/10.1186/1471-2407-13-489
Smith, D H, Christensen, I J, Jensen, N F, Markussen, B, Müller, S, Nielsen, H J, Brünner, N & Nielsen1,7, K V 2013, ' An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort ', BMC Cancer, vol. 13, 13:489 . https://doi.org/10.1186/1471-2407-13-489
Background: Platinum-based chemotherapy has long been used in the treatment of a variety of cancers andfunctions by inducing DNA damage. ERCC1 and ERCC4 are involved in the removal of this damage and havepreviously been implicated in resistance to pl
Autor:
Ib Jarle Christensen, Kirsten Vang Nielsen, Maria Unni Rømer, Sune Boris Nygaard, Hans Jørgen Nielsen, Nils Brünner, Ben Vainer, Signe Lykke Nielsen, David Hersi Smith, Sven Müller
Publikováno v:
Journal of Clinical Oncology. 30:475-475
475 Background: TOP1 inhibitor treatment is frequently being used in combination therapy of metastatic CRC. This study aims to reveal whether TOP1 gene copy number associates with patient prognosis, since such a relationship may have significant impl
Autor:
Yves Pommier, Birgitta R. Knudsen, Amit Roy, Hongliang Zhang, James H. Doroshow, Thomas D. Pfister, David Hersi Smith, Niels Frank Jensen, Keli Agama, Nils Brünner, Jan Stenvang, Maria Unni Rømer
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Jensen, N F, Agama, K, Roy, A, Smith, D H, Pfister, T D, Rømer, M U, Zhang, H-L, Doroshow, J H, Knudsen, B R, Stenvang, J, Brünner, N & Pommier, Y 2016, ' Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations ', Journal of Experimental and Clinical Cancer Research (Online), vol. 35, no. 1, 56 . https://doi.org/10.1186/s13046-016-0335-x
Jensen, N F, Agama, K, Roy, A, Smith, D H, Pfister, T D, Rømer, M U, Zhang, H-L, Doroshow, J H, Knudsen, B R, Stenvang, J, Brünner, N & Pommier, Y 2016, ' Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations ', Journal of Experimental and Clinical Cancer Research (Online), vol. 35, no. 1, 56 . https://doi.org/10.1186/s13046-016-0335-x
BACKGROUND: DNA topoisomerase I (Top1) is a DNA unwinding protein and the specific target of the camptothecin class of chemotherapeutic drugs. One of these, irinotecan, acting through its active metabolite SN-38, is used in the treatment of metastati